Patents Assigned to Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd.
  • Soluble tumor necrosis factor receptor mutant
    Patent number: 8454969
    Abstract: A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha and lymphotoxin related diseases.
    Type: Grant
    Filed: January 12, 2009
    Date of Patent: June 4, 2013
    Assignees: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd.
    Inventors: Yanjun Liu, Tong Yang, Yijun Shen, Jinsong Wu, Fang Wu
  • Soluble Tumor Necrosis Factor Receptor Mutant
    Publication number: 20110117082
    Abstract: A soluble tumor necrosis factor receptor 2 (TNFRII) mutant has an amino acid substitution at position 92Glu compared with the wild TNFRII. The mutant improves the cytotoxicity capacity of neutralizing TNFalpha and lymphotoxin. The mutant and fusion protein comprising it are useful for the treatment of TNFalpha and lymphotoxin related diseases.
    Type: Application
    Filed: January 12, 2009
    Publication date: May 19, 2011
    Applicants: Shanghai Fudan-Zhangjiang Bio-pharmaceutical Co., Ltd., Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd.
    Inventors: Yanjun Liu, Tong Yang, Yijun Shen, Jinsong Wu, Fang Wu